ST Tobokalova¹*, KA Nogoybaeva¹ and JT Aitieva²

¹Kyrgyz State Medical Institute of Postgraduate Education N. S.B. Daniarov, Bishkek, Kyrgyz Republic
²Osh State university, Osh, Kyrgyz Republic

*Corresponding Author: ST Tobokalova, Kyrgyz State Medical Institute of Postgraduate Education N. S.B. Daniarov, Bishkek, Kyrgyz Republic.

Received: May 31, 2021; Published: July 19, 2021

Abstract

  Thus, to date, the only approved etiotropic drug for viral hepatitis D is - peg IFN, which is combined with nucleoside analogues in the presence of an HBV viral load. According to systematic data for example, the use of humanized mice as a laboratory model made it possible to better understand the issues of hepatitis virus replication and integration D with host cells. As a result, researchers have developed several antiviral drugs aimed at different parts of the pathogenesis of HDV infection. Prenylation inhibitor-Lonafarnib, which blocks the exit of HDV particles from the cell; nucleic acid polymers (NAP) (REP2139Ca), an oligopeptide that mainly affects the penetration of the virus into the cell, and Myrcludex B- lipopeptide, preventing the formation of HDV RNA in initialized hepatocytes, undergoing various phases of testing in different countries.

Keywords: Hepatitis D Infection; Antiviral Therapy; Lonafarnib; Myrcludex B

References

1. Patel EU., et al. “Prevalence of hepatitis B and hepatitis D virus infections in the United States, 2011‐2016”. Clinical Infectious Diseases 69 (2019): 709‐712.
2. Romeo R., et al. “A 28-Year Study of the Course of Hepatitis Δ Infection: A Risk Factor for Cirrhosis and Hepatocellular Carcinoma”. Gastroenterology 136 (2009): 1629-1638.
3. Vincent TL., et al. “Targeting the Host for New Therapeutic Perspectives in Hepatitis D”. Clinical Medicine 9 (2020): 1.
4. Rizzetto M., et al. “Treatment of chronic delta hepatitis with α-2 recombinant interferon”. Journal of Hepatology 3 (1986): S229-S233.
5. Wedemeyer H., et al. “Peginterferon plus adefovir versus either drug alone for hepatitis delta”. The New England Journal of Medicine 364 (2011): 322-331.
6. Wranke A., et al. “Current management of HBV/HDV coinfection and future perspectives”. Current Hepatology Reports 14 (2015): 284-292.
7. Zoulim F., et al. “Quantification of HbsAg in nucleos (t)ide-naive patients treated for chronic hepatitis B with entecavir with or without tenofovir in the be-low study”. Journal of Hepatology 62 (2015): 56-63.
8. Lampertico P., et al. “EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection”. Journal of Hepatology (2017).
9. Soriano V., et al. “Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients”. AIDS 28 (2014): 2389-2394.
10. Wedemeyer H., et al. “Peginterferon plus adefovir versus either drug alone for hepatitis delta”. The New England Journal of Medicine 364 (2011): 322-331.
11. Wedemeyer H., et al. “O4 prolonged therapy of hepatitis delta for 96 weeks with pegylated-interferon-α-2A plus tenofovir or placebo does not prevent HDV RNA relapse after treatment: The HIDIT-2 study”. Journal of Hepatology 60 (2014): S2-S3.
12. Florian A., et al. “Hepatitis Delta Virus: Replication Strategy and Upcoming Therapeutic Options for a Neglected Human Pathogen”. Viruses 7 (2017): 172.
13. Koh C., et al. “Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: A proof-of-concept randomised, double-blind, placebo-controlled phase 2a trial”. Lancet Infectious Disease 15 (2015): 1167-1174.
14. Rizzetto M and A Ciancio. “The prenylation inhibitor, lonafarnib: A new therapeutic strategy against hepatitis delta”. Lancet Infectious Disease 15 (2015): 1119-1120.
15. Bordier BB., et al. “In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus”. Journal of Clinical Investigation 112 (2003): 407-414.
16. Mijimolle N., et al. “Protein farnesyltransferase in embryogenesis, adult homeostasis, and tumor development”. Cancer Cell 7 (2005): 313-324.
17. Palsuledesai CC., et al. “Protein prenylation: Enzymes, therapeutics, and biotechnology applications”. ACS Chemical Biology 10 (2015): 51-62.
18. Yurdaydin C. “Recent advances in managing hepatitis D. Version 1”. F1000 Research 6 (2017): 1596.
19. Bazinet M., et al. “Hdv2 o-09: Rep 2139 monotherapy and combination therapy with pegylated interferon: Safety and potent reduction of HbsAg and HDV RNA in patients with chronic HBV/HDV co-infection”. Journal of Viral Hepatitis 22 (2015): 5-6.
20. Noordeen F., et al. “Therapeutic antiviral effect of the nucleic acid polymer rep 2055 against persistent duck hepatitis B virus infection”. PloS ONE 10 (2015): e0140909.
21. “Replicor” (2017).
22. Schulze A., et al. “Fine mapping of pre-s sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction”. Journal of Virology 84 (2010): 1989-2000.
23. Meier A., et al. “Myristoylated PRES1-domain of the hepatitis B virus l-protein mediates specific binding to differentiated hepatocytes”. Hepatology 58 (2013): 31-42.
24. Lempp FA., et al. “Hepatitis delta virus: Insights into a peculiar pathogen and novel treatment options”. Nature Reviews Gastroenterology and Hepatology 13 (2016): 580-589.
25. Nkongolo S., et al. “Cyclosporin a inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor”. Journal of Hepatology 60 (2014): 723-731.
26. Haag M. “Quantitative bile acid profiling by liquid chromatography quadrupole time-of-flight mass spectrometry: Monitoring hepatitis B therapy by a novel Na (+)-taurocholate cotransporting polypeptide inhibitor”. Analytical and Bioanalytical Chemistry 407 (2015): 6815-6825.
27. Slijepcevic D., et al. “Impaired uptake of conjugated bile acids and hepatitis B virus PRES1-binding in Na (+) -taurocholate cotransporting polypeptide knockout mice”. Hepatology 62 (2015): 207-219.
28. Lin H., et al. “Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency: Conjugated hypercholanemia without a clear clinical phenotype”. Hepatology 61 (2015): 260-267.
29. Deng M. “Clinical and molecular study of a pediatric patient with sodium taurocholate cotransporting polypeptide deficiency”. Experimental and Therapeutic Medicine 12 (2016): 3294-3300.
30. Blank A., et al. “First-in-human application of the first-in-class hepatitis B and hepatitis D virus entry inhibitor myrcludex B”. Journal of Hepatology 65 (2016): 483-489.
31. Bogomolov P., et al. “A proof-of-concept phase 2a clinical trial with HBV/HDV entry inhibitor myrcludex b”. Hepatology 60 (2014): 1279A-1280A.
32. Bogomolov P., et al. “Treatment of chronic hepatitis D with the entry inhibitor myrcludex b—First results of a phase Ib/Iia study”. Journal of Hepatology 65 (2016): 490-498.
33. Elazar M and JS Glenn. “Emerging concepts for the treatment of hepatitis delta”. Current Opinion on Virology 24 (2017): 55-59.

Citation

Citation: ST Tobokalova., et al. “The Hepatitis B with Delta Agent Problems of Therapy”.Acta Scientific Medical Sciences 6.1 (2022): 78-84.

Copyright

Copyright: © 2022 ST Tobokalova., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.